Stock MACK MERRIMACK PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
14.73 USD 0.00% Intraday chart for Merrimack Pharmaceuticals, Inc. +0.07% +9.84%
Mar. 27 Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT
Mar. 07 Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 51.5 42.09 92.19 52.43 153.7 192
Enterprise Value (EV) 1 -4.902 25.51 78.15 38.23 134.2 173.2
P/E ratio -1.27 x -2.43 x -30.4 x -21.4 x -100 x -162 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA 0.08 x -1.26 x -28.1 x - - -
EV / FCF 0.12 x -1.57 x -46.9 x 52.8 x -185 x -153 x
FCF Yield 856% -63.5% -2.13% 1.89% -0.54% -0.65%
Price to Book 0.88 x 2.43 x 5.76 x 3.7 x 8.46 x 10.3 x
Nbr of stocks (in thousands) 13,343 13,363 13,380 13,410 13,410 14,321
Reference price 2 3.860 3.150 6.890 3.910 11.46 13.41
Announcement Date 3/6/19 3/12/20 3/10/21 3/9/22 3/9/23 3/7/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -60.2 -20.24 -2.784 - - -
EBIT 1 -64.28 -22.47 -5.012 -2.616 -2.174 -2.176
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -68.46 -22.74 -3.014 -2.452 -1.541 -1.169
Net income 1 -40.51 -17.33 -3.028 -2.455 -1.544 -1.181
Net margin - - - - - -
EPS 2 -3.036 -1.298 -0.2263 -0.1831 -0.1142 -0.0826
Free Cash Flow 1 -41.96 -16.21 -1.666 0.724 -0.7248 -1.129
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/6/19 3/12/20 3/10/21 3/9/22 3/9/23 3/7/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 56.4 16.6 14 14.2 19.4 18.9
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -42 -16.2 -1.67 0.72 -0.72 -1.13
ROE (net income / shareholders' equity) -78.4% -55.9% -18.2% -16.3% -9.24% -6.22%
ROA (Net income/ Total Assets) -39% -25.9% -17% -10.4% -7.86% -6.97%
Assets 1 103.8 67.03 17.81 23.67 19.65 16.94
Book Value Per Share 2 4.410 1.290 1.200 1.060 1.350 1.310
Cash Flow per Share 2 1.500 1.240 1.050 1.060 1.370 0.4200
Capex 1 0.12 - - - - -
Capex / Sales - - - - - -
Announcement Date 3/6/19 3/12/20 3/10/21 3/9/22 3/9/23 3/7/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MERRIMACK PHARMACEUTICALS, INC. Stock Merrimack Pharmaceuticals, Inc.
+9.84% 214M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MACK Stock
  4. Financials Merrimack Pharmaceuticals, Inc.